BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25792355)

  • 1. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
    Heuser M; Meggendorfer M; Cruz MM; Fabisch J; Klesse S; Köhler L; Göhring G; Ganster C; Shirneshan K; Gutermuth A; Cerny-Reiterer S; Krönke J; Panagiota V; Haferlach C; Koenecke C; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Ehrlich S; Stamer K; Döhner K; Valent P; Schlegelberger B; Kroeger N; Ganser A; Haase D; Haferlach T; Thol F
    Leukemia; 2015 Sep; 29(9):1942-5. PubMed ID: 25792355
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
    Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
    J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
    Schneider RK; Ademà V; Heckl D; Järås M; Mallo M; Lord AM; Chu LP; McConkey ME; Kramann R; Mullally A; Bejar R; Solé F; Ebert BL
    Cancer Cell; 2014 Oct; 26(4):509-20. PubMed ID: 25242043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
    Kuendgen A
    Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
    [No Abstract]   [Full Text] [Related]  

  • 7. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
    Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
    Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis.
    Zemanova Z; Michalova K; Buryova H; Brezinova J; Kostylkova K; Bystricka D; Novakova M; Sarova I; Izakova S; Lizcova L; Ransdorfova S; Krejcik Z; Merkerova MD; Dohnalova A; Siskova M; Jonasova A; Neuwirtova R; Cermak J
    Leuk Res; 2014 May; 38(5):537-44. PubMed ID: 24636338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
    Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
    Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
    [No Abstract]   [Full Text] [Related]  

  • 13. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
    Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
    Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial MDS with 5q- abnormality.
    Grimwade DJ; Stephenson J; De Silva C; Dalton RG; Mufti GJ
    Br J Haematol; 1993 Jul; 84(3):536-8. PubMed ID: 8217806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5q- syndrome: a scientific and clinical update.
    Tefferi A; Mathew P; Noël P
    Leuk Lymphoma; 1994 Aug; 14(5-6):375-8. PubMed ID: 7812195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265P.
    Zagaria A; Coccaro N; Tota G; Anelli L; Minervini A; Casieri P; Cellamare A; Minervini CF; Brunetti C; Ricco A; Orsini P; Cumbo C; Specchia G; Albano F
    Blood Cells Mol Dis; 2015 Jan; 54(1):51-2. PubMed ID: 25159121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived CK1α mutations enhance MDMX inhibition of p53.
    Liu X; Huang Q; Chen L; Zhang H; Schonbrunn E; Chen J
    Oncogene; 2020 Jan; 39(1):176-186. PubMed ID: 31462704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDS with del(5q) and associated cKIT D816V positive mastocytosis.
    Chan N; Tan SY; Opat S; Shortt J
    Pathology; 2012 Aug; 44(5):492-3. PubMed ID: 22777071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.